Ratings by Wells Fargo (Ben Burnett)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/20/2026 | WAVE Life Sciences | WVE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2026 | Liquidia Technologies | LQDA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2026 | Insmed | INSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/8/2026 | PTC Therapeutics | PTCT | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/7/2026 | MannKind | MNKD | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/7/2026 | United Therapeutics Corp. | UTHR | Upgrade | Overweight (Equal Weight) |
596.76 (544.33) |
-8.79% | Details | |
| 5/6/2026 | Ultragenyx Pharma | RARE | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/6/2026 | Alkermes | ALKS | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/28/2026 | MannKind | MNKD | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/31/2026 | United Therapeutics Corp. | UTHR | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 3/27/2026 | WAVE Life Sciences | WVE | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/23/2026 | United Therapeutics Corp. | UTHR | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 3/23/2026 | Liquidia Technologies | LQDA | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/23/2026 | Insmed | INSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/11/2026 | Rapport Therapeutics | RAPP | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/6/2026 | Liquidia Technologies | LQDA | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/5/2026 | Keros Therapeutics | KROS | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/27/2026 | MannKind | MNKD | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/26/2026 | United Therapeutics Corp. | UTHR | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 2/26/2026 | Alkermes | ALKS | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/20/2026 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/20/2026 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 2/12/2026 | WAVE Life Sciences | WVE | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/30/2025 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 12/18/2025 | Savara | SVRA | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/16/2025 | Insmed | INSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/9/2025 | WAVE Life Sciences | WVE | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/11/2025 | WAVE Life Sciences | WVE | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/11/2025 | MannKind | MNKD | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/11/2025 | Keros Therapeutics | KROS | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/5/2025 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 10/31/2025 | Insmed | INSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/30/2025 | United Therapeutics Corp. | UTHR | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 10/20/2025 | WAVE Life Sciences | WVE | New Coverage | Overweight (N/A) |
7.81 (6.04) |
-22.66% | Details | |
| 10/20/2025 | United Therapeutics Corp. | UTHR | New Coverage | Underweight (N/A) |
433.34 (596.76) |
37.71% | Details | |
| 10/20/2025 | Tectonic Therapeutics Inc. | TECX | New Coverage | Overweight (N/A) |
17.26 (30.59) |
77.23% | Details | |
| 10/20/2025 | Savara | SVRA | New Coverage | Overweight (N/A) |
3.61 (5.78) |
60.11% | Details | |
| 10/20/2025 | Ultragenyx Pharma | RARE | New Coverage | Overweight (N/A) |
32.63 (28.76) |
-11.86% | Details | |
| 10/20/2025 | PTC Therapeutics | PTCT | New Coverage | Overweight (N/A) |
65.95 (82.13) |
24.53% | Details | |
| 10/20/2025 | MannKind | MNKD | New Coverage | Overweight (N/A) |
5.47 (3.93) |
-28.15% | Details | |
| 10/20/2025 | Liquidia Technologies | LQDA | New Coverage | Overweight (N/A) |
22.48 (74.04) |
229.36% | Details | |
| 10/20/2025 | Keros Therapeutics | KROS | New Coverage | Overweight (N/A) |
13.83 (11.00) |
-20.46% | Details | |
| 10/20/2025 | Insmed | INSM | New Coverage | Overweight (N/A) |
165.76 (102.15) |
-38.37% | Details |
